Asthma | Landscape & Forecast | Disease Landscape & Forecast

Publish date: June 2019

Login to access report

The asthma market consists of many well-established therapies, including inhaled agents (e.g., GlaxoSmithKline’s Advair/Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s Spiriva), oral drugs (e.g., montelukast), and biologics (e.g., Roche/Novartis’s Xolair, GlaxoSmithKline’s Nucala). However, market dynamics are evolving as branded-generic and generic alternatives to inhaled blockbuster agents continue to launch and new biologics targeting niche populations within the severe asthma segment are approved. These events have increased—and will continue to increase—competition in this lucrative market. With the impending entry of additional biological therapies, the launch of branded-generic and generic inhaled drugs in new markets, and the potential launch of LABA/LAMA/ICS combination agents, the asthma market is poised to experience change over the next decade.

Questions Answered:

  • What are KOLs’ insights on current inhaled branded, branded-generic, and generic treatment options? What is/will be the market impact of branded-generic and generic inhaled therapies?
  • What are KOLs’ perceptions of the currently marketed asthma biologics (Xolair, Nucala, Teva’s Cinqair/Cinqaero, AstraZeneca’s Fasenra)? Where in the treatment algorithm do physicians fit these drugs? What drives physicians’ choice of a biologic in severe refractory asthma patients?
  • How will the market evolve over the next ten years given the launch of additional inhaled, oral, and biological products? Will the entry of triple LABA/LAMA/ICS combination agents have a substantial effect on the sales and patient share of currently marketed asthma therapies? Where do physicians see these triple therapies fitting in the treatment algorithm?

Scope:

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: 39 country-specific interviews with thought leaders.

Epidemiology: Number of diagnosed and drug-treated prevalent cases of asthma; number of diagnosed and drug-treated prevalent cases of intermittent/mild persistent and moderate/severe persistent asthma.

Emerging therapies: Preregistered: 1 drug; Phase III: 8 drugs; Phase II: 11 drugs; coverage of 2 select preclinical/Phase I products.

Table of contents

  • Disease Landscape & Forecast
    • Key Updates
      • June 2019
      • October 2018
      • August 2018
      • June 2018
    • Market Outlook
      • Key Findings
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Asthma?
        • What Factors Are Constraining the Market for Asthma?
      • Drug-Class-Specific Trends
        • Inhaled Corticosteroids
        • Long-Acting Beta2 Agonists
        • LABA/ICS Combinations
        • Long-Acting Muscarinic Antagonists
        • Long-Acting Beta2 Agonists/Long-Acting Muscarinic Antagonists/Inhaled Corticosteroid Combinations
        • Leukotriene Inhibitors
        • CRTh2 Antagonists
        • Methylxanthines
        • Anti-Immunoglobulin E Agents
        • Anticytokines
        • Oral Corticosteroids
        • Short-Acting Beta2 Antagonists
        • Short-Acting Muscarinic Antagonists
        • Short-Acting Beta2 Agonists/Short-Acting Muscarinic Antagonist Combinations
    • Forecast
    • Etiology and Pathophysiology
      • Disease Overview
      • Etiology
      • Disease Pathophysiology
        • Pathophysiology and Phenotypes
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
        • Note About Our Epidemiology Estimates
      • Epidemiology Populations
        • Diagnosed Prevalent Cases of Asthma (Symptomatic or Symptoms Medically Controlled)
        • Diagnosed Prevalent Cases of Asthma by Severity
        • Diagnosed Cases of Asthma
        • Drug-Treated Cases of Asthma
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Inhaled Corticosteroids
        • Long-Acting Beta2 Agonists
        • Long-Acting Beta2 Agonist/Inhaled Corticosteroid Fixed-Dose Combinations
        • Leukotriene Inhibitors
        • Long-Acting Muscarinic Antagonists
        • Anti-Immunoglobulin E Agents
        • IL-5 Antagonists
        • Short-Acting Beta2 Agonists
      • Medical Practice
        • Overview
        • Treatment Guidelines
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Asthma
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Notable Developments Among Key Emerging Therapies for Asthma
        • Anticytokines
        • LABA/ICS FDCs
        • LABA/LAMA/ICS FDCs
        • CRTh2 Antagonists
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for Asthma
      • Key Discontinuations and Failures in Asthma
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • Agents Included in Our Market Analysis
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Asthma Bibliography

Author(s): Shubhendu Ghosh, PhD; Elena Kozhemyakina, PhD; Alison Isherwood, MSc, MRes, PhD

Shubhendu Ghosh, is a Business Insights Analyst on the Immune and Inflammatory Disorders team at Decision Resources Group, with a primary focus on asthma. Prior to joining DRG, Shubhendu was an Associate Editor at Nature Structural & Molecular Biology and a Copy Editor at Nature Medicine. He was also a Scientific and Developmental Editor at Nature Research Editing Service. Shubhendu received his in Biomedical Sciences from the University of Massachusetts Medical School after completing a B. Sc. in Microbiology from Delhi University and an M. Sc. In Biotechnology from Madurai Kamaraj University.

Elena Kozhemyakina, PhD, is a Senior Business Insight Analyst at Decision Resources, Inc., specializing in pharmaceutical market analysis of the immune system disorders with expertise in Systemic Lupus Erythematosus, asthma, Crohn’s disease and ulcerative colitis. Prior to joining Decision Resources, Dr. Kozhemyakina completed a postdoctoral fellowship at Harvard Medical School, where she investigated molecular mechanisms involved in limb patterning, cartilage formation and pathogenesis of osteoarthritis. She published multiple peer-reviewed papers focused on molecular signalling of developmental disorders.

Alison Isherwood, , joined Decision Resources Group in 2008, as an Epidemiologist. Alison holds a in Medical Microbiology, Masters by Research in the Life Sciences and a in Epidemiology all from the University of Edinburgh. Prior to joining Decision Resources Inc., she was working on her in Molecular Virology, specializing on the severe acute respiratory syndrome (SARS) coronavirus, at the University of Reading. In her role at Decision Resources Group, Alison is currently an Epidemiology team lead as well as project managing custom epidemiology work in multiple therapy areas. Alison’s area of specialization at DRG is cancer, particularly breast cancer.